Skip to content

ConfidenHTTM system safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients and/or potential candidates for a renal sympathetic denervation (RDN) procedure

ConfidenHTTM system safety and performance of diagnostic electrical mapping of renal nerves in hypertensive patients and/or potential candidates for a renal sympathetic denervation (RDN) procedure - ConfidenHT

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
NL-OMON
Registry ID
NL-OMON43150
Enrollment
10
Registered
2016-12-23
Start date
2016-10-19
Completion date
Unknown
Last updated
2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertensie High blood pressure hypertension

Interventions

Through a puncture of the groin (under local anesthesia) a catheter is advanced towards the renal artery around which several nerves are located which play an important role in the control of blood
Hypertension
Renal nerve mapping

Sponsors

Pythagoras Medical Ltd.
Lead Sponsor

Eligibility

Age
18 Years to 64 Years

Inclusion criteria

Inclusion criteria: - Signed written informed consent. - Age >18 years and 45. - A patient who is mentally competent with the ability to understand and comply with the requirements of the study. - The patient agrees to attend all follow-up evaluations and is willing to complete required exams and tests.

Exclusion criteria

Exclusion criteria: - Previous participation in another study with any investigational drug or device within the past 30 days. - Relevant renal artery disease (% diameter stenosis>30%, aneurysm or fibromuscular dysplasia). - Known secondary causes of hypertension. - The patient has a life expectancy * 12 months. - The patient has undergone prior renal denervation, renal stenting, and/or abdominal aortic stent grafts. - The patient has chronic oxygen use other than nocturnal support for sleep apnea. - The patient has type I diabetes mellitus. - The patient has had a previous organ transplant or is awaiting a renal transplant. - Active implantable medical device (e.g. ICD or CRT-D; neuromodulator/spinal stimulator; baroreflex stimulator). - The patient has triple ipsilateral artery ostia. - Moderate to severe valvular heart disease. - The patient has other concomitant conditions that may adversely affect the patient or the study outcome. - Female who is pregnant, nursing or planning to become pregnant. - Documented contraindication or allergy to contrast medium not amenable to treatment.

Design outcomes

Primary

MeasureTime frame
The incidence of serious adverse events (system and/or procedure related events).

Secondary

MeasureTime frame
Arterial blood pressure changes to renal nerve stimulation.

Countries

Greece

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)